•
Dec 31, 2022

ClearPoint Neuro Q4 2022 Earnings Report

Reported record revenues.

Key Takeaways

ClearPoint Neuro reported a 21% year-over-year increase in fourth quarter revenue, reaching $5.2 million. The company's full-year revenue grew by 26% to $20.6 million. They also reiterated their 2023 revenue forecast of between $25 and $27 million.

Reported fourth quarter 2022 revenue of $5.2 million, a 21% year-over-year increase compared with the fourth quarter of 2021.

Reported revenue of $20.6 million for the full year 2022, an increase of 26% over 2021 and representing the eighth consecutive year of growth.

Increased biologics and drug delivery revenue to $9.1 million for the full year 2022, a 34% increase over 2021.

Cash and short-term investments totaled $37.5 million as of December 31, 2022.

Total Revenue
$5.17M
Previous year: $4.28M
+20.8%
EPS
-$0.18
Previous year: -$0.19
-5.3%
Gross Profit
$3.32M
Previous year: $3.29M
+0.8%
Cash and Equivalents
$27.6M
Previous year: $54.1M
-49.0%
Free Cash Flow
-$3.1M
Previous year: -$3.59M
-13.5%
Total Assets
$55.5M
Previous year: $65.6M
-15.4%

ClearPoint Neuro

ClearPoint Neuro

ClearPoint Neuro Revenue by Segment

Forward Guidance

ClearPoint Neuro expects growth of more than 20% in 2023 and is reiterating its 2023 revenue forecast of between $25 and $27 million.

Positive Outlook

  • Expected growth of more than 20% in 2023
  • Competitiveness of laser system
  • Cadence of pharma partners’ continuing progress through the global regulatory process for new gene and cell therapies

Challenges Ahead

  • Impact of the COVID-19 pandemic
  • Global instability
  • Supply chain disruptions
  • Labor shortages
  • Macroeconomic and inflationary conditions